One of the main limitations of our meta-analysis is the small number of studies included, as there are currently only a few clinical trials using [99mTc]Tc-PSMA SPECT/CT for the diagnosis of prostate cancer and our meta-analysis results were based only on patient studies. This evidence concerns the gene FOLH1 and prostate cancer.